Integra LifeSciences Forecasts Q1 Fiscal Year 2024 Revenues Of $360M-$365M, Representing Reported Growth Of Approximately -5.5% To -4.1% And Organic Growth Of Approximately -5.1% To -3.7%. Versus Consensus Of $380.91M
Portfolio Pulse from Benzinga Newsdesk
Integra LifeSciences projects Q1 FY2024 revenues to be between $360M-$365M, indicating a reported and organic decline of approximately -5.5% to -4.1% and -5.1% to -3.7%, respectively, falling short of the consensus estimate of $380.91M.
February 28, 2024 | 11:10 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Integra LifeSciences projects lower-than-expected Q1 FY2024 revenues, indicating a decline in both reported and organic growth.
Integra LifeSciences' forecasted revenues for Q1 FY2024 are significantly below the consensus estimates, indicating a potential negative impact on investor sentiment and stock price in the short term. The reported and organic declines suggest underlying challenges in the company's operations or market conditions that could concern investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100